Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases. Transgene’s programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells.
The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer.
Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
September 29, 2014
TG4010 TIME Phase 2b trial ESMO 2014 Congress poster available here